Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Farmers Insurance
Daiichi Sankyo
US Army
Accenture
Healthtrust
Chubb
Novartis
Cantor Fitzgerald
Deloitte
Queensland Health

Generated: August 23, 2017

DrugPatentWatch Database Preview

JUXTAPID Drug Profile

« Back to Dashboard

Which patents cover Juxtapid, and what generic Juxtapid alternatives are available?

Juxtapid is a drug marketed by Aegerion and is included in one NDA. There are seven patents protecting this drug.

This drug has eighty-six patent family members in thirty-six countries.

The generic ingredient in JUXTAPID is lomitapide mesylate. There are two drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the lomitapide mesylate profile page.

Summary for Tradename: JUXTAPID

Patents:7
Applicants:1
NDAs:1
Suppliers / Packagers: see list1
Bulk Api Vendors: see list30
Clinical Trials: see list5
Patent Applications: see list2
Formulation / Manufacturing:see details
Drug Prices:see details
DailyMed Link:JUXTAPID at DailyMed
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Aegerion
JUXTAPID
lomitapide mesylate
CAPSULE;ORAL203858-005Apr 23, 2015RXYesNo► Subscribe► Subscribe ► Subscribe
Aegerion
JUXTAPID
lomitapide mesylate
CAPSULE;ORAL203858-004Apr 23, 2015RXYesNo► Subscribe► Subscribe ► Subscribe
Aegerion
JUXTAPID
lomitapide mesylate
CAPSULE;ORAL203858-006Apr 23, 2015RXYesYes► Subscribe► SubscribeYY ► Subscribe
Aegerion
JUXTAPID
lomitapide mesylate
CAPSULE;ORAL203858-005Apr 23, 2015RXYesNo► Subscribe► Subscribe► Subscribe
Aegerion
JUXTAPID
lomitapide mesylate
CAPSULE;ORAL203858-006Apr 23, 2015RXYesYes► Subscribe► Subscribe ► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Tradename: JUXTAPID

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Aegerion
JUXTAPID
lomitapide mesylate
CAPSULE;ORAL203858-001Dec 21, 2012► Subscribe► Subscribe
Aegerion
JUXTAPID
lomitapide mesylate
CAPSULE;ORAL203858-002Dec 21, 2012► Subscribe► Subscribe
Aegerion
JUXTAPID
lomitapide mesylate
CAPSULE;ORAL203858-003Dec 21, 2012► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Tradename: JUXTAPID

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
5,595,872 Nucleic acids encoding microsomal trigyceride transfer protein► Subscribe
6,034,098 Inhibitors of microsomal triglyceride transfer protein and method► Subscribe
5,789,197 Microsomal triglyceride transfer protein► Subscribe
5,739,135 Inhibitors of microsomal triglyceride transfer protein and method► Subscribe
5,883,099 Inhibitors of microsomal triglyceride transfer protein and method► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Tradename: JUXTAPID

Country Document Number Estimated Expiration
Mexico9705005► Subscribe
Poland322003► Subscribe
HungaryT70613► Subscribe
Lithuania97152► Subscribe
New Zealand264372► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Tradename: JUXTAPID

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
0634Netherlands► SubscribePRODUCT NAME: LOMITAPIDE OF HET PIPERIDINE N-OXIDE DAARVAN, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT; REGISTRATION NO/DATE: EU/1/13/851/001-003 20130805
00634Netherlands► SubscribePRODUCT NAME: LOMITAPIDE EN ELKE THERAPEUTISCH EQUIVALENTE VORM DAARVAN, ZOALS DOOR HET BASISOCTROOI BESCHERMD; REGISTRATION NO/DATE: EU/1/13/851/001-003 20130731
2014001Lithuania► SubscribePRODUCT NAME: LOMITAPIDUM; REGISTRATION NO/DATE: EU/1/13/851/001, 2013 07 31 EU/1/13/851/002, 2013 07 31 EU/1/13/851/003 20130731
2014000003Germany► SubscribePRODUCT NAME: LOMITAPID ODER EIN PHARMAZEUTISCH ANNEHMBARES SALZ DAVON ODER DAS PIPERIDIN-N-OXID DAVON; REGISTRATION NO/DATE: EU/1/13/851/001-003 20130731
6 5001-2014Slovakia► SubscribePRODUCT NAME: LOMITAPID; REGISTRATION NO/DATE: EU/1/13/851/001 - EU/1/13/851/003 20130805
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Moodys
Novartis
Federal Trade Commission
QuintilesIMS
Medtronic
Fish and Richardson
Queensland Health
US Army
Farmers Insurance
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot